BioNTech SE - ADR vs Monolithic Power Systems Inc — how do they compare? BioNTech SE - ADR trades at $93.34 (market cap $23.31B), while Monolithic Power Systems Inc trades at $1,430.96 (market cap $68.90B). The key difference: Monolithic Power Systems Inc is far larger — about 3× BioNTech SE - ADR's market cap, and Monolithic Power Systems Inc pays a 0.57% dividend while BioNTech SE - ADR pays none. Which is the better fit depends on your goals.
| BNTX | MPWR | |
|---|---|---|
Market Cap | $23.31B | $68.90B |
Sector | Health | Utilities |
52-Week High | $119.34 | $1.69K |
52-Week Low | $83.89 | $820.74 |
Enterprise Value | $6.60B | $67.51B |
Dividend Yield | — | 0.57% |
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $93.27, up 0.51% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported Q2 2026 revenue of $106 million, missing expectations, and lowered its full-year sales outlook due to weak COVID-19 vaccine demand. Despite negative net income margins and cash outflows, BNTX maintains a strong cash position of $16.78 billion and is advancing its oncology pipeline with 14 pivotal clinical trials.
The outlook is mixed: analyst consensus is strongly bullish with a $121 price target, but declining COVID revenue and ongoing losses pose significant risks. Investment opportunity hinges on successful pipeline development, while near-term headwinds from vaccine demand softness and leadership transition require careful monitoring.
MPWR is trading at $1,437.94, up 4.12% today, reflecting strong momentum after recent earnings beats. The stock shows a bullish technical trend with support at $1,386 and resistance at $1,425. Fundamentally, Q2 2026 revenue surged to $980.6M, driven by 164.3% growth in Enterprise Data, with net income margin expanding to 24.5%. Analyst sentiment is overwhelmingly positive, with 88% recommending Buy and a consensus price target of $1,870.
Outlook remains favorable given robust AI-driven demand and upward earnings revisions, but risks include high valuation multiples (P/E 85.55) and potential double-ordering concerns. The stock offers growth exposure but requires monitoring of execution and competitive pressures in the semiconductor sector.
Trailing returns across standard periods
Latest headlines on both assets
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →Monolithic Power Systems, Inc. is a global leader in high-performance, analog, and mixed-signal semiconductors. The company specializes in power management solutions, providing integrated circuits (ICs) for a wide range of applications, including computing, automotive, industrial, and communications. MPWR's proprietary process technology is designed to deliver highly energy-efficient and compact power solutions, positioning the company as a key supplier for the next generation of electronic devices.
Read more on MPWR →